Angiotech Pharmaceuticals, Inc. - SWOT, Strategy and Corporate Finance Report
Published: January 2013 · Publisher: MarketLine
Angiotech Pharmaceuticals, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, etc.
- Description
- Table of Contents
- Ask a Question
Angiotech Pharmaceuticals, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360° view of the company.
Features:
- Detailed information on Angiotech Pharmaceuticals, Inc. required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Angiotech Pharmaceuticals, Inc. in the form of a SWOT analysis
- An in-depth view of the business model of Angiotech Pharmaceuticals, Inc. including a breakdown and examination of key business segments
- Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Angiotech Pharmaceuticals, Inc.
- Intelligence on Angiotech Pharmaceuticals, Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Angiotech Pharmaceuticals, Inc., such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Highlights:
Angiotech Pharmaceuticals (Angiotech)* is a medical device company. It is engaged in the discovery, development, and marketing of innovative technologies. The company operates in the US, Europe and other regions. It is headquartered in Vancouver, Canada and employed 1,368 people as of December 31, 2010. The company recorded revenues of $246.2 million during the financial year ended December 2010 (FY2010), a decrease of 12% compared with FY2009. The operating loss of the company was $20.1 million during FY2010, as compared to operating profit of $23.1 million in FY2009. The net loss was $66.8 million in FY2010, as compared to net loss of $22.9 million in FY2009. * The company has filed under the US Bankruptcy Code to effectuate the Companies’ Creditors Arrangement Act (CCAA) Proceedings in the US as set forth in the CCAA Plan.
Reasons to Purchase:
- Gain understanding of Angiotech Pharmaceuticals, Inc. and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess Angiotech Pharmaceuticals, Inc. as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers' businesses better
- Stay up to date on Angiotech Pharmaceuticals, Inc.’s business structure, strategy and prospects
Features:
- Detailed information on Angiotech Pharmaceuticals, Inc. required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Angiotech Pharmaceuticals, Inc. in the form of a SWOT analysis
- An in-depth view of the business model of Angiotech Pharmaceuticals, Inc. including a breakdown and examination of key business segments
- Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Angiotech Pharmaceuticals, Inc.
- Intelligence on Angiotech Pharmaceuticals, Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Angiotech Pharmaceuticals, Inc., such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Highlights:
Angiotech Pharmaceuticals (Angiotech)* is a medical device company. It is engaged in the discovery, development, and marketing of innovative technologies. The company operates in the US, Europe and other regions. It is headquartered in Vancouver, Canada and employed 1,368 people as of December 31, 2010. The company recorded revenues of $246.2 million during the financial year ended December 2010 (FY2010), a decrease of 12% compared with FY2009. The operating loss of the company was $20.1 million during FY2010, as compared to operating profit of $23.1 million in FY2009. The net loss was $66.8 million in FY2010, as compared to net loss of $22.9 million in FY2009. * The company has filed under the US Bankruptcy Code to effectuate the Companies’ Creditors Arrangement Act (CCAA) Proceedings in the US as set forth in the CCAA Plan.
Reasons to Purchase:
- Gain understanding of Angiotech Pharmaceuticals, Inc. and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess Angiotech Pharmaceuticals, Inc. as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers' businesses better
- Stay up to date on Angiotech Pharmaceuticals, Inc.’s business structure, strategy and prospects
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
Company Snapshot
Angiotech Pharmaceuticals, Inc.: Company Overview
Angiotech Pharmaceuticals, Inc.: Overview and Key Facts
Angiotech Pharmaceuticals, Inc.: Overview
Angiotech Pharmaceuticals, Inc.: Key Facts
Angiotech Pharmaceuticals, Inc.: Key Employees
Angiotech Pharmaceuticals, Inc.: Key Employee Biographies
Angiotech Pharmaceuticals, Inc.: Major Products and Services
Angiotech Pharmaceuticals, Inc.: Company History
Angiotech Pharmaceuticals, Inc.: Locations and Subsidiaries
Angiotech Pharmaceuticals, Inc.: Key Competitors
Angiotech Pharmaceuticals, Inc.: Company Analysis
Angiotech Pharmaceuticals, Inc.: Business Description
Angiotech Pharmaceuticals, Inc.: SWOT Analysis
Angiotech Pharmaceuticals, Inc.: SWOT Overview
Angiotech Pharmaceuticals, Inc.: Strengths
Angiotech Pharmaceuticals, Inc.: Weaknesses
Angiotech Pharmaceuticals, Inc.: Opportunities
Angiotech Pharmaceuticals, Inc.: Threats
Angiotech Pharmaceuticals, Inc.: Corporate Financial Deals Activity
Angiotech Pharmaceuticals, Inc.: Financial Deals Overview
Angiotech Pharmaceuticals, Inc.: Targets and Partners
Angiotech Pharmaceuticals, Inc.: Top Deals 2009 - 2013YTD*
Angiotech Pharmaceuticals, Inc.: Mergers and Acquisitions
Angiotech Pharmaceuticals, Inc.: Partnership
Angiotech Pharmaceuticals, Inc.: Divestments
Angiotech Pharmaceuticals, Inc.: Recent Developments
Angiotech Pharmaceuticals, Inc.: News and Events Summary
Angiotech Pharmaceuticals, Inc.: Contracts
Angiotech Pharmaceuticals, Inc.: Corporate Governance
Angiotech Pharmaceuticals, Inc.: Financial Deals
Angiotech Pharmaceuticals, Inc.: Financial Performance
Angiotech Pharmaceuticals, Inc.: Regulatory and Legal Events
Angiotech Pharmaceuticals, Inc.: Research & Development
Angiotech Pharmaceuticals, Inc.: Strategy and Operations
Appendix
Contact Us
Methodology
Definitions
List of Tables
Table 1: Angiotech Pharmaceuticals, Inc.: Key Facts
Table 2: Angiotech Pharmaceuticals, Inc.: Key Employees
Table 4: Angiotech Pharmaceuticals, Inc.: Key Competitors
Table 5: Angiotech Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (2009 - YTD*2013)
Table 6: Angiotech Pharmaceuticals, Inc.: Targets and Partners
Table 7: Angiotech Pharmaceuticals, Inc.: Top Deals 2009 - 2013YTD*
Table 8: Angiotech Pharmaceuticals, Inc.: M&A Volume and Value Trend (2009 - YTD*2013)
Table 9: Angiotech Pharmaceuticals, Inc.: M&A Activity by Geography (2009 - YTD*2013)
Table 10: Angiotech Pharmaceuticals, Inc.: Partnership Volume and Value Trend (2009 - YTD*2013)
Table 11: Angiotech Pharmaceuticals, Inc.: Partnership Trend by Deal Type (2009 - YTD*2013)
Table 12: Angiotech Pharmaceuticals, Inc.: Divestments Volume and Value Trend (2009 - YTD*2013)
Table 13: Angiotech Pharmaceuticals, Inc.: Divestments by Geography (2009 - YTD*2013)
Table 14: Angiotech Pharmaceuticals, Inc.: News and Events Summary
Table 15: Angiotech Pharmaceuticals, Inc.: Contracts
Table 16: Angiotech Pharmaceuticals, Inc.: Corporate Governance
Table 17: Angiotech Pharmaceuticals, Inc.: Financial Deals
Table 18: Angiotech Pharmaceuticals, Inc.: Financial Performance
Table 19: Angiotech Pharmaceuticals, Inc.: Regulatory and Legal Events
Table 20: Angiotech Pharmaceuticals, Inc.: Research & Development
Table 21: Angiotech Pharmaceuticals, Inc.: Strategy and Operations
List of Figures
Figure 1: Angiotech Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (2009 - YTD*2013)
Figure 2: Angiotech Pharmaceuticals, Inc.: M&A Volume and Value Trend (2009 - YTD*2013)
Figure 3: Angiotech Pharmaceuticals, Inc.: M&A Activity by Geography (2009 - YTD*2013)
Figure 4: Angiotech Pharmaceuticals, Inc.: Partnership Volume and Value Trend (2009 - YTD*2013)
Figure 5: Angiotech Pharmaceuticals, Inc.: Partnership Trend by Deal Type (2009 - YTD*2013)
Figure 6: Angiotech Pharmaceuticals, Inc.: Divestments Volume and Value Trend (2009 - YTD*2013)
Figure 7: Angiotech Pharmaceuticals, Inc.: Divestments by Geography (2009 - YTD*2013)
Angiotech Pharmaceuticals, Inc.: Company Overview
Angiotech Pharmaceuticals, Inc.: Overview and Key Facts
Angiotech Pharmaceuticals, Inc.: Overview
Angiotech Pharmaceuticals, Inc.: Key Facts
Angiotech Pharmaceuticals, Inc.: Key Employees
Angiotech Pharmaceuticals, Inc.: Key Employee Biographies
Angiotech Pharmaceuticals, Inc.: Major Products and Services
Angiotech Pharmaceuticals, Inc.: Company History
Angiotech Pharmaceuticals, Inc.: Locations and Subsidiaries
Angiotech Pharmaceuticals, Inc.: Key Competitors
Angiotech Pharmaceuticals, Inc.: Company Analysis
Angiotech Pharmaceuticals, Inc.: Business Description
Angiotech Pharmaceuticals, Inc.: SWOT Analysis
Angiotech Pharmaceuticals, Inc.: SWOT Overview
Angiotech Pharmaceuticals, Inc.: Strengths
Angiotech Pharmaceuticals, Inc.: Weaknesses
Angiotech Pharmaceuticals, Inc.: Opportunities
Angiotech Pharmaceuticals, Inc.: Threats
Angiotech Pharmaceuticals, Inc.: Corporate Financial Deals Activity
Angiotech Pharmaceuticals, Inc.: Financial Deals Overview
Angiotech Pharmaceuticals, Inc.: Targets and Partners
Angiotech Pharmaceuticals, Inc.: Top Deals 2009 - 2013YTD*
Angiotech Pharmaceuticals, Inc.: Mergers and Acquisitions
Angiotech Pharmaceuticals, Inc.: Partnership
Angiotech Pharmaceuticals, Inc.: Divestments
Angiotech Pharmaceuticals, Inc.: Recent Developments
Angiotech Pharmaceuticals, Inc.: News and Events Summary
Angiotech Pharmaceuticals, Inc.: Contracts
Angiotech Pharmaceuticals, Inc.: Corporate Governance
Angiotech Pharmaceuticals, Inc.: Financial Deals
Angiotech Pharmaceuticals, Inc.: Financial Performance
Angiotech Pharmaceuticals, Inc.: Regulatory and Legal Events
Angiotech Pharmaceuticals, Inc.: Research & Development
Angiotech Pharmaceuticals, Inc.: Strategy and Operations
Appendix
Contact Us
Methodology
Definitions
List of Tables
Table 1: Angiotech Pharmaceuticals, Inc.: Key Facts
Table 2: Angiotech Pharmaceuticals, Inc.: Key Employees
Table 4: Angiotech Pharmaceuticals, Inc.: Key Competitors
Table 5: Angiotech Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (2009 - YTD*2013)
Table 6: Angiotech Pharmaceuticals, Inc.: Targets and Partners
Table 7: Angiotech Pharmaceuticals, Inc.: Top Deals 2009 - 2013YTD*
Table 8: Angiotech Pharmaceuticals, Inc.: M&A Volume and Value Trend (2009 - YTD*2013)
Table 9: Angiotech Pharmaceuticals, Inc.: M&A Activity by Geography (2009 - YTD*2013)
Table 10: Angiotech Pharmaceuticals, Inc.: Partnership Volume and Value Trend (2009 - YTD*2013)
Table 11: Angiotech Pharmaceuticals, Inc.: Partnership Trend by Deal Type (2009 - YTD*2013)
Table 12: Angiotech Pharmaceuticals, Inc.: Divestments Volume and Value Trend (2009 - YTD*2013)
Table 13: Angiotech Pharmaceuticals, Inc.: Divestments by Geography (2009 - YTD*2013)
Table 14: Angiotech Pharmaceuticals, Inc.: News and Events Summary
Table 15: Angiotech Pharmaceuticals, Inc.: Contracts
Table 16: Angiotech Pharmaceuticals, Inc.: Corporate Governance
Table 17: Angiotech Pharmaceuticals, Inc.: Financial Deals
Table 18: Angiotech Pharmaceuticals, Inc.: Financial Performance
Table 19: Angiotech Pharmaceuticals, Inc.: Regulatory and Legal Events
Table 20: Angiotech Pharmaceuticals, Inc.: Research & Development
Table 21: Angiotech Pharmaceuticals, Inc.: Strategy and Operations
List of Figures
Figure 1: Angiotech Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (2009 - YTD*2013)
Figure 2: Angiotech Pharmaceuticals, Inc.: M&A Volume and Value Trend (2009 - YTD*2013)
Figure 3: Angiotech Pharmaceuticals, Inc.: M&A Activity by Geography (2009 - YTD*2013)
Figure 4: Angiotech Pharmaceuticals, Inc.: Partnership Volume and Value Trend (2009 - YTD*2013)
Figure 5: Angiotech Pharmaceuticals, Inc.: Partnership Trend by Deal Type (2009 - YTD*2013)
Figure 6: Angiotech Pharmaceuticals, Inc.: Divestments Volume and Value Trend (2009 - YTD*2013)
Figure 7: Angiotech Pharmaceuticals, Inc.: Divestments by Geography (2009 - YTD*2013)
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.